Everything below concerns AOD-9604. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-10-05. Where a claim depends on a specific study, the study is described rather than over-claimed.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized form |
| Solubility | Soluble in water | Also soluble in aqueous buffers |
| Storage temperature | -20°C or below | Protect from light and moisture |
| Analytical method | RP-HPLC | Purity and identity assessment |
| Mass confirmation | Mass spectrometry | Verifies molecular mass |
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
Bacteria (particularly those that are catalase-positive) Staphylococcus aureus. Serratia marcescens. Listeria species. E. coli. Klebsiella species. Pseudomonas cepacia, a.k.a. Burkholderia cepacia. Nocardia. Fungi Aspergillus species. Aspergillus has a propensity to cause infection in people with CGD and of the Aspergillus species, Aspergillus fumigatus seems to be most common in CGD. Candida species. Patients with CGD can usually resist infections of catalase-negative bacteria but are susceptible to catalase-positive bacteria. Catalase is an enzyme that catalyzes the breakdown of hydrogen peroxide in many organisms. In infections caused by organisms that lack catalase (catalase-negative), the host with CGD is successfully able to "borrow" hydrogen peroxide being made by the organism and use it to fight off the infection. In infections by organisms that have catalase (catalase-positive), this "borrowing mechanism" is unsuccessful because the enzyme catalase first breaks down any hydrogen peroxide that would be borrowed from the organism. Therefore in the CGD patient, hydrogen peroxide cannot be used to make oxygen radicals to fight infection, leaving the patient vulnerable to infection by catalase-positive bacteria.
=== Kernel === Johnson founded Kernel in 2016, investing $100 million of his own money to launch the company. The company later shifted its focus to building hardware that measures electrical and hemodynamic signals produced by the brain. Documents released by the United States Department of Justice in February 2026 show that Johnson had email correspondence and meetings with Jeffrey Epstein in 2017 about Kernel. After the documents were released and reported by various outlets, Johnson confirmed that the meeting took place and stated that he cut off contact following one video conference. Johnson was introduced to Epstein by Alex Klokus. In 2020, Kernel demonstrated a pair of helmet-like devices that can see and record brain activity. Studies may include Alzheimer's disease, aging, concussions, meditation states, and strokes. The company has said the devices may be used to help paralyzed individuals communicate, or people with mental health challenges access new therapies.
In a November 2004 interview, Boyarsky said that although the team would like to pursue a Bloodlines sequel, the decision was Activision's. Before their closure, Troika had begun development of a workable prototype based on another of White Wolf's tabletop role-playing games, Werewolf: The Apocalypse, set in the same universe as Vampire: The Masquerade. According to Boyarsky, the prototype was one small area built using assets taken from Bloodlines, and allowed the player to play as a werewolf, or a human capable of turning into one. Paradox Interactive obtained the rights to Bloodlines in 2015, following their purchase of White Wolf. Paradox CEO Fredrik Wester confirmed that a sequel was possible, stating "when the time is right I guess a sequel will find its place in the market." Vampire: The Masquerade – Bloodlines 2 was announced in March 2019. Initially developed by Seattle-based Hardsuit Labs, the game was to be written by Bloodlines's lead-writer Brian Mitsoda, and Cara Ellison. Set in Seattle, the plot cast the player as a fledgling thinblood vampire with relatively weak abilities, who was turned as part of a masquerade-violating "mass embrace" of humans. However, in 2020, Mitsoda, Ellison, and creative director Ka'ai Cluney left the project. In February 2021, Hardsuit Labs was also removed as developer and replaced with The Chinese Room. The change also resulted in a different plot which follows an elder vampire, Phyre, after they are awoken in modern Seattle. The sequel was released on 21 October 2025. A 2018 actual play web series, titled L.A.
Sources: en.wikipedia.org
== Periwound issues == Periwound issues affect the integrity and healthy functionality of the skin surrounding the wound and may include maceration, excoriation, dry (scaly) skin, eczema, callus (hyperkeratosis), infection, inflammation.
== Education and career == Brenner graduated from Wesleyan University with a bachelor's degree in biology in 1983. After working for the biotechnology companies Chiron Corporation and DNAX Research Institute, Brenner attended graduate school at Stanford University School of Medicine. At Stanford he worked with Robert S. Fuller, receiving his Ph.D. in Cancer Biology in 1993. Brenner conducted post-doctoral research at Brandeis University with Gregory Petsko and Dagmar Ringe. Brenner then joined the faculty at Thomas Jefferson University, where he worked from 1996 to 2003, becoming Director of the Structural Biology & Bioinformatics Program in 2000. He moved to Dartmouth Medical School in 2003, serving as associate director for Basic Sciences at Norris Cotton Cancer Center (now named Dartmouth Cancer Center) from 2003 to 2009. In 2009 he joined the University of Iowa (UI) as Professor and Head of Biochemistry. In 2010 he was awarded the Roy J. Carver Chair of Biochemistry at UI, holding that position until 2020. In 2020, Brenner joined City of Hope National Medical Center in Duarte, California as the inaugural chair of a new department of diabetes and cancer metabolism created to focus at the intersection of metabolic disturbances with diseases such as cancer and diabetes.
By the time of the First Schleswig War, one-third of Schleswig and half of South Schleswig spoke German as their first language. By the time of the Second Schleswig War in 1864, half of Schleswig and the vast majority of South Schleswig spoke German as their first language.
Sources: en.wikipedia.org
=== Gastrointestinal disease === Evidence shows that an elevated PCT above .5 ng/mL could help diagnose infectious complications of inflammatory bowel disease such as abdominal abscesses, bacterial enterocolitis etc. PCT can be effective in early recognition of infections in IBD patients and decisions on whether to prescribe antibiotics.
The colony's participation in the Empire Air Training Scheme is described in J F MacDonald's War History of Southern Rhodesia as "undoubtedly Southern Rhodesia's greatest single contribution to the Allied victory", an assertion corroborated by Robert Blake in his 1977 History of Rhodesia. The Rhodesian Air Training Group (RATG) under Air Vice-Marshal Sir C W Meredith eventually operated 11 aerodromes, requiring a huge national effort to build, maintain and staff—at the scheme's peak more than a fifth of the white population was involved. This judicious management of skills and resources allowed the territory to make a much larger contribution to the Allied war effort than if it had simply sent all its manpower into the field. Southern Rhodesia was regarded as an ideal location for air training for a number of reasons. It was far from the hostilities, firmly pro-British and had excellent weather throughout the year. The British Air Ministry resolved to outsource training to the colony amid some urgency in late 1939 after EATS took a long time to get going in Canada. The RATG was the last EATS group to be formed, but the first to start training airmen; it also turned out fully qualified pilots before any of the others, doing so for the first time in November 1940. The programme originally called only for an initial training wing and six schools, but this was expanded to eight flying schools and a school for bomb aimers, navigators and air gunners. There were two air firing and bombing ranges.
The Leaning Tower of Pizza was a proposed 30-story slanted skyscraper that would have housed Domino's Pizza's operations at its Domino's Farms campus near Ann Arbor, Michigan. In the mid-1980s, Monaghan asked Taliesin Associated Architects, the inheritors of Frank Lloyd Wright's practice, to erect a structure based on an un-built tower that Wright designed in 1956 for Chicago called the Golden Beacon. Sometime during the planning of the tower, Monaghan and the Taliesin architects parted company, allegedly because both parties felt the project may have not served justice to the spirit of Wright's architecture. Monaghan then went to Gunnar Birkerts, the architect of Domino's unusual half-mile (800 m) long headquarters office building who came up with a design for a tower that would rise at a 15-degree angle with a swooping top reminiscent of the forms of Wright's late work. Birkerts' design, no doubt, had serious intent, but would immediately and forever be dubbed with the nickname "The Leaning Tower of Pizza" after Italy's Leaning Tower of Pisa. The structure was never built but a 50-foot (15 m) tall scale model stands at the proposed site on Domino Pizza headquarters in Ann Arbor Charter Township, Michigan, outside of Ann Arbor.
It enables referendums and plebiscites and establishes environmental protection as a fundamental state principle. The former Hanoverian Amt Neuhaus with its parishes of Dellien, Haar, Kaarßen, Neuhaus (Elbe), Stapel, Sückau, Sumte and Tripkau as well as the villages of Neu Bleckede, Neu Wendischthun and Stiepelse in the parish of Teldau and the historic Hanoverian region in the forest district of Bohldamm in the parish of Garlitz transferred with effect from 30 June 1993 from Mecklenburg-Vorpommern to Lower Saxony (Lüneburg district). From these parishes the new municipality of Amt Neuhaus was created on 1 October 1993. In 1998 Gerhard Glogowski succeeded Gerhard Schröder who became Federal Chancellor. Because he had been linked with various scandals in his home city of Brunswick, he resigned in 1999 and was replaced by Sigmar Gabriel. From 2003 to his election as Federal President in 2010 Christian Wulff was minister president in Lower Saxony. The Osnabrücker headed a CDU-led coalition with the FDP as does his successor, David McAllister. After the elections on 20 January 2013 McAllister was deselected.
Sources: en.wikipedia.org
Reversed-phase HPLC is used to assess purity, and mass spectrometry confirms molecular mass. Amino acid analysis can verify composition. These methods are standard for peptide characterization.
Lyophilized powder should be stored at -20°C or lower, protected from light and moisture. Reconstituted solutions are less stable and should be aliquoted to avoid freeze-thaw cycles. Always follow supplier instructions.
Variability in purity, counterion content, and residual solvents is possible. Independent testing and certificates of analysis help verify quality. Microbial contamination can occur if handling is not sterile.
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.